GRIN Therapeutics Receives FDA Breakthrough Therapy Designation for Radiprodil
Designation for treatment of seizures associated with GRIN-related neurodevelopmental disorder in patients with gain-of-function mutations recognizes radiprodil's potential to demonstrate substantial improvement over available symptom-based therapyCompany preparing to initiate Phase